Merck Sharp + Dohme Corp.

Beijing Genomics Institute at Shenzhen

Devan V Mehrotra

Xun Xu

Peter M Shaw

Junhua Li

Gregory J Opiteck

Peggy H Wong

Joshua McElwee

Steven Greenberg

Zifang Guo

Rebecca L Blanchard

Robin Mogg

Mary Beth Dorr

Judong Shen

Joshua Mcelwee

The present invention provides genetic markers on human chromosome 6 that are associated with a beneficial response to a treatment that targets() toxin B (TcdB), e.g. a TcdB antibody. These TcdB treatment response markers are useful, inter alia, to identify patients who are most likely to benefit from treatment that targets TcdB in methods of treating patients having a disease susceptible to treatment with a TcdB antibody, and in methods for selecting the most appropriate therapy for such patients. The invention also provides antibodies, drug products, and kits useful with the TcdB Treatment response markers of the invention.

Human genetic markers associated with response to treatments that target clostridium difficile toxin B

The present invention provides genetic markers on human chromosome 1 that are associated with a beneficial response to CRTH2 receptor antagonists. These CRTH2 receptor antagonist response markers are useful, inter alia, to identify patients who are most likely to benefit from treatment with CRTH2 receptor antagonist compositions and drug products, in methods of treating patients having a disease susceptible to treatment with a CRTH2 receptor antagonist, and in methods for selecting the most appropriate therapy for such patients.

Genetic markers associated with response to CRTH2 receptor antagonists

Growing community of inventors

Lansdale, PA, United States of America

Devan V Mehrotra